SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not</u> complete, correct, or legible, the authorization process can be delayed.

Drug Requested: Syndros[®] (dronabinol) Oral Solution

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:	
Member Sentara #:	
Prescriber Name:	
	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Author Drug Form/Strength:	rization may be delayed if incomplete.
	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:
	elow all that apply. All criteria must be met for approval. To cation, including lab results, diagnostics, and/or chart notes, must be

□ Patient is 18 years of age or older

DIAGNOSES: Check diagnosis that applies. All criteria following diagnosis <u>must</u> be met for approval.

□ Anorexia in patients with AIDS

□ Prescriber is an Infectious Disease provider specializing in HIV/AIDS treatment

AND

Deatient has a diagnosis of wasting syndrome due to AIDS

AND

(Continued on next page)

□ Patient has had a 30 day trial and failure of megestrol acetate

AND

Patient has had trial and failure of at least three (3) months of dronabinol generic capsules titrated to maximum effective dose

Chemotherapy-induced nausea and vomiting

□ Prescriber is an Oncologist

AND

□ Patient has a diagnosis of cancer with ongoing chemotherapy treatment

AND

 Patient has had insufficient response from combination treatment for acute/delayed chemotherapyinduced nausea/vomiting with standard treatment (such as ondansetron, dexamethasone or aprepitant).
 Please list therapies tried:

AND

D Patient has had trial and failure of olanzapine for refractory nausea/vomiting

AND

Patient has had 30-day trial and failure of dronabinol generic capsules titrated to maximum effective dose

OR

□ Patient has difficulty swallowing capsules due to tumor resection or radiation therapy

** Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>